Butorphanol Nasal Spray CIV
Generic Name and Formulations:
Butorphanol tartrate 1mg/spray; nasal spray.
Various generic manufacturers
Indications for Butorphanol Nasal Spray:
Pain management when opioid analgesia is appropriate.
≥18 years: initially 1 spray in 1 nostril, repeat after 60–90 minutes if needed (Elderly: 90–120 minutes); may repeat in 3–4 hours. Or, may give 1 spray in each nostril, may repeat after 3–4 hours.
<18 years: not recommended.
Head injury. Increased intracranial pressure. Biliary tract surgery. Respiratory, cardiac, renal, or hepatic dysfunction. MI. Ventricular dysfunction. Coronary insufficiency. Hypertension. May precipitate withdrawal in narcotic addicts. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Potentiates CNS depression with alcohol, other CNS depressants. Nasal vasoconstrictors delay onset. May be antagonized by concomitant (within 30 minutes) sumatriptan nasal spray.
Sedation, dizziness, nasal congestion, insomnia, GI upset, respiratory depression, sweating, hypo- or hypertension, rash, vasodilation, palpitation, tinnitus, respiratory and CNS effects.
Formerly known under the brand name Stadol NS.
Nasal Spray 2.5mL (8–15 sprays)—Contact supplier.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA Status Could Inform Pancreatic Cancer Management
- Polypharmacy and Cancer
- Adoptive Cell Therapy in Solid Tumors Demonstrates Robust Antitumor Effects
- Novel Approaches for the Treatment of Primary Central Nervous System Lymphoma
- Heterogeneity of Drug Resistance in EGFR-Mutant Non-Small Cell Lung Cancer